Block listing Application

RNS Number : 3332N
Oxford Biomedica PLC
25 July 2014







Block listing Application


Oxford, UK - 25 July 2014: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Company") a leading gene- and cell-therapy company, announces that applications have been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange's markets for a block listing of securities totalling 15 million ordinary shares of 1 pence each (the "Ordinary Shares").


The Ordinary Shares are being reserved under a block listing and will be issued from time to time pursuant to the following schemes:

·     OXB Share Option Scheme (10 million Ordinary Shares); and

·     LTIP (5 million Ordinary Shares).


It is expected that admission of the Ordinary Shares will become effective on 28 July 2014. The Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.




For further information, please contact:



Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer


Tel: +44 (0)1865 783 000


Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications



Tel: +44 (0)20 3709 5700




Notes for editors


About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at and



This information is provided by RNS
The company news service from the London Stock Exchange